Trevi Therapeutic…
USUSDTrevi Therapeutics Inc (US:TRVI) — Biotechnology: Pharmaceutical Preparations. Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 1. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie įmonę
- Svetainė
- trevitherapeutics.com
- Sektorius
- Health Care · Biotechnology: Pharmaceutical Preparations
- Būstinė
- NEW HAVEN, United States
- Generalinis direktorius
- Ms. Jennifer L. Good
- Darbuotojai
- 34
- Apyvartoje esančios akcijos
- 142.48 mln. 2026-07-31 duomenimis
- Laisvai apyvartinės akcijos
- 118.32 mln.
- Rinkos kapitalizacija
- 1.92 mlrd. USD
- Insaideriai
- 0.63%
- Instituciniai investuotojai
- 107.73%
- Šaka (SIC)
- Pharmaceutical Preparations
Aprašymas
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Biržos ir tikeriai
| Birža | Tikeris | Valiuta | Kaina | Tipas |
|---|---|---|---|---|
| US USA Stocks | TRVI | USD | 12.825 -2.40% | paprastosios akcijos |
Dividendai
Dividendų išmokų nerasta (patikrinta 09.10.2026). Įmonė greičiausiai nemoka dividendų.
Šios savaitės naujienos
Naujienų iš įmonės svetainės kol kas nėra.
Didžiausi akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos data |
|---|---|---|---|
| NEA Management Company,… | 9.28% | 13.22 mln. | 2026-06-30 |
| FMR, LLC | 8.82% | 12.56 mln. | 2026-06-30 |
| Blackrock Inc. | 7.83% | 11.16 mln. | 2026-06-30 |
| Frazier Life Sciences Ma… | 6.98% | 9.94 mln. | 2026-06-30 |
| Wellington Management Gr… | 3.99% | 5.68 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 3.88% | 5.53 mln. | 2026-06-30 |
| Vivo Capital, LLC | 3.58% | 5.09 mln. | 2026-06-30 |
| Woodline Partners LP | 2.86% | 4.08 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.84% | 4.05 mln. | 2026-06-30 |
| Vestal Point Capital, LP | 2.18% | 3.1 mln. | 2026-06-30 |
| MPM Bioimpact LLC | 2.16% | 3.07 mln. | 2026-06-30 |
| iShares Trust-iShares Ru… | 1.91% | 2.72 mln. | 2026-08-31 |
| MUTUAL FUND SERIES TRUST… | 1.87% | 2.66 mln. | 2026-06-30 |
| Fidelity Select Portfoli… | 1.67% | 2.37 mln. | 2026-07-31 |
| Fidelity Securities Fund… | 1.37% | 1.95 mln. | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 1.35 mln. | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.82% | 1.17 mln. | 2026-07-31 |
| Fidelity Mt. Vernon Stre… | 0.73% | 1.04 mln. | 2026-07-31 |
| AB CAP FUND, INC.-AB Sma… | 0.72% | 1.03 mln. | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.7% | 996 857 | 2026-08-31 |
| SCIASCIA THOMAS R (Offic… | ≈0.16% | 221 373 | 2025-03-25 |
| GOOD JENNIFER L (Chief E… | ≈0.15% | 213 313 | 2025-03-21 |
| BASKETT FOREST (Benefici… | — | — | 2025-04-17 |
| BEHBAHANI ALI (Beneficia… | — | — | 2025-04-17 |
| CHANG CARMEN (Beneficial… | — | — | 2025-04-17 |
| FLORENCE ANTHONY A JR (B… | — | — | 2025-04-17 |
| MAKHZOUMI MOHAMAD (Benef… | — | — | 2025-04-17 |
| NEW ENTERPRISE ASSOCIATE… | — | — | 2025-04-17 |
| SANDELL SCOTT D (Benefic… | — | — | 2025-04-17 |
| WALKER PAUL EDWARD (Bene… | — | — | 2025-04-17 |
